Back

GOG 104

Intraperitoneal Cisplatin Plus Intravenous Cyclophosphamide Versus Intravenous Cisplatin Plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer

Date of Publication:

December 26, 1996

Pubmed Link:
https://pubmed.ncbi.nlm.nih.gov/8960474/
Hypothesis:

Does IP cisplatin improve survival over IV cisplatin when combined with IV cyclophosphamide after surgical resection of advanced epithelial ovarian cancer?

Control Arm(s):

IV cyclophosphamide 600mg/m2 day 1IV cisplatin 100mg/m2 day 1q3wks x6 cycles

Experimental Arm(s):

IV cyclophosphamide 600mg/m2 day 1IP cisplatin 100mg/m2q3wks x6 cycles

Primary End Point:

OS

Inclusion Criteria:

PDS to ≤2cm residualepithelial ovarian cancerstage III

Exclusion Criteria:
Results:

IV (n=279) vs IP (n=267):58% in both groups completed 6 cycles of cisplatincomplete response: 36% vs 47%median OS: 41 vs 49 mos (SS)more leukopenia/neuro toxicity in IV arm

Conclusions:

IP cisplatin improves survival in women with stage III epithelial ovarian cancer after resection to ≤2cm residual disease

Reviewer:
Olga T Filippova